Apr 24, 2024
Publications
Refined analytical pipeline for the pharmacodynamic assessment of T-cell responses to vaccine antigens
Publication: Frontiers in Immunology
Authors: Michail Angelos Pavlidis, Nadia Viborg, Mads Lausen, Birgitte Rønø and Daniela Kleine-Kohlbrecher
Apr 17, 2024
Press releases
Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01
Evaxion announces that the first patient in its EVX-01 Phase 2 trial in metastatic melanoma received the last vaccine dose in combination with KEYTRUDA® (NCT05309421).
Apr 17, 2024
Publications
Startups probe hidden viruses in the ‘dark genome’ to treat disease
Publication: Nature Biotechnology
Author: Michael Eisenstein
Apr 2, 2024
Press releases
Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection
Evaxion is pleased to announce the successful conclusion of a series of large non-rodent animal infection studies, testing antigens from Evaxion’s preclinical EVX-B1 vaccine candidate against Staphylococcus aureus (S. aureus).
Mar 27, 2024
Press releases
Evaxion Announces Business Update and Full Year 2023 Financial Results
Evaxion today provides a business update and announces full year 2023 financial results.
Mar 19, 2024
Presentations
R&D Day on AI-Immunology™ March 19, 2024
Take a look at the presentations from our Research & Development (R&D) Day on AI-Immunology™ captured in a series of videos.
Mar 19, 2024
Press releases
Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform
Evaxion hosts a Research & Development (R&D) Day focusing on its core AI-Immunology™ platform.
Mar 14, 2024
Publications
Personalized Neoantigen DNA Cancer Vaccines: Current Status and Future Perspectives
Publication: Journal of Cellular Immunology
Author: Nadia Viborg, Daniela Kleine-Kohlbrecher and Birgitte Rønø
Feb 29, 2024
Press releases
Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology Innovations
Evaxion announces that it will host a Research & Development (R&D) Day focusing on its core AI-Immunology™ platform on March 19, 2024, at 14:00 - 18:00 CET / 8:00 a.m. - 12:00 a.m. EST.
Feb 20, 2024
Press releases
Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD
Evaxion announces the successful completion of the initial phases of its vaccine collaboration with MSD (tradename of Merck & Co., Inc., Rahway, NJ, USA). The vaccine development project combines both organizations' unique capabilities and know-how.
Feb 7, 2024
Press releases
Evaxion Regains Compliance with Nasdaq Minimum Bid Price Requirement
Evaxion announces that on February 05, 2024, it received a Notification Letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company had regained compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule 5550(a)(2).
Feb 1, 2024
Press releases
Evaxion Biotech Announces Pricing of $15 Million Public Offering
Evaxion announces the pricing of a public offering of an aggregate of 3,750,000 of its American Depositary Shares (“ADSs”) (or pre-funded warrants in lieu thereof) and warrants to purchase up to 3,750,000 ADSs at a combined public offering price of $4.00 per ADS (or pre-funded warrant in lieu thereof) and accompanying warrant.
Evaxion Media kit
Subscribe to our Newsletter
Be the first to know about news, milestones and events at Evaxion by subscribing to our newsletter. You'll only hear from us when it's important, and can unsubscribe at any time.